Levamole 75 mg/ml Oral Solution

Pajjiż: Ingilterra

Lingwa: Ingliż

Sors: VMD (Veterinary Medicines Directorate)

Ingredjent attiv:

Levamisole Hydrochloride

Disponibbli minn:

Chanelle Pharmaceuticals Manufacturing Ltd

Kodiċi ATC:

QP52AE01

INN (Isem Internazzjonali):

Levamisole Hydrochloride

Għamla farmaċewtika:

Oral solution

Tip ta 'preskrizzjoni:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Grupp terapewtiku:

Cattle, Sheep

Żona terapewtika:

Anthelmintic

L-istatus ta 'awtorizzazzjoni:

Authorized

Data ta 'l-awtorizzazzjoni:

2007-09-12

Karatteristiċi tal-prodott

Revised: April 2014
AN: 01709/2013
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Levamole 75 mg/ml Oral Solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Levamisole Hydrochloride 7.5% w/v
EXCIPIENT(S):
Sodium Metabisulphite
0.1% w/v
Tartazine (E102)
0.00375% w/v
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral solution.
A yellow coloured clear solution.
4.
CLINICAL PARTICULARS
4.1.
TARGET SPECIES
Cattle and Sheep
4.2.
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
A broad spectrum anthelmintic for the treatment and control of
gastro-intestinal
and pulmonary nematode infections in cattle and sheep, effective
against
mature and developing immature stages of the following
levamisole-susceptible
major nematode worm species:
GASTRO-INTESTINAL WORMS: _ Trichostrongylus _ spp.,_ Cooperia _ spp.,
_ Ostertagia_
spp.
(except
inhibited
Ostertagia
larvae
in
cattle),
_Haemonchus _
spp.,
_Nematodirus _spp., _Bunostomum_ spp., _Oesophagostomum _spp.,
_Chabertia _spp.
LUNGWORMS: _Dictyocaulus_ spp.
Not effective against Type II winter scour.
4.3.
CONTRAINDICATIONS
Animals should not be treated simultaneously or within 14 days before
or after
use with Organophosphorous compounds or diethylcarbamazine citrate.
Revised: April 2014
AN: 01709/2013
Page 2 of 6
4.4.
SPECIAL WARNINGS FOR EACH TARGET SPECIES
The product may be given to young, pregnant and lactating animals, but
due
regard must always be paid to the animals physical condition and the
presence
of inter-current disease. When a dosing gun is used to administer the
product,
care should be taken to avoid the occurrence of dosing gun
pharyngitis.
Care should be taken to avoid the following practices because they
increase the
risk of development of resistance and could ultimately result in
ineffective
therapy:
•
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
•
Underdosing, which may be due to underestimation of body weight,
misadministration of